Company Overview

Update
Status:
Acquired by Sangamo BioSciences
Founders:
Stephen Sherwin
Headquarters:
San Diego, CA
Funding:
$39.50M
Categories:
Biotechnology

Ceregene is a biotechnology company that treats neurodegenerative disorders using the delivery of nervous system growth factors.

Description

Update

Ceregene is a private, San Diego-based biotechnology company focused on the treatment of major neurodegenerative disorders using the delivery of nervous system growth factors. Their clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor, which is about to enter Phase 2 studies for the treatment of Alzheimer's disease, and CERE-120, which recently completed a Phase 2 trial in Parkinson's disease and is currently being evaluated for future development. CERE-135 and CERE-140 are in preclinical development for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and ocular diseases, respectively.

Current Team (2)

Update

Board Members and Advisors (1)

Update

Funding Rounds (2) - $39.50M

Update

Investors (6)

Update

Offices/Locations (1)

Update
  • Office

    9381 Judicial Dr.

    Ste. 130

    San Diego, CA 92121

    USA

Images (1)

Update
  • C2e0cc776ef6a00e7009eaec439438ec